Miao Wang, Guo Junshuang, Zhang Shuyu, Shen Nannan, Shang Xiaoping, Liu Furong, Lu Warren, Xu Jianghai, Teng Junfang
Neuro-Intensive Care Unit, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Medical Records Management, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Neurol. 2021 Nov 4;12:711674. doi: 10.3389/fneur.2021.711674. eCollection 2021.
There is currently no effective treatment for Japanese encephalitis, which has a high rate of morbidity and mortality. This study assessed the effectiveness of a ganciclovir, methylprednisolone, and immunoglobulin combination (TAGMIC) therapy in decreasing cognitive impairment and mortality among patients with Japanese encephalitis. We retrospectively assessed the clinical data of 31 patients diagnosed with Japanese encephalitis, who were admitted to an intensive care unit. Patients were divided into the TAGMIC and non-TAGMIC group according to their treatment regime. We compared the 60-day, 6-month, and overall mortality and survival curves between groups. We also compared Barthel Index scores, Montreal Cognitive Assessment (MoCA) scores, and diffusion tensor imaging (DTI) results. There was no significant difference in the 30-day mortality rate or Kaplan-Meier survival curve between groups. The 60-day, 6-month, and overall mortality rates in the TAGMIC group were significantly reduced ( = 0.043, = 0.018, and = 0.018, respectively) compared with the non-TAGMIC group (0, 0, 0 vs. 31.25, 37.5, 37.5%, respectively). The 60-day, 6-month, and overall Kaplan-Meier survival curves were significantly different between groups ( = 0.020, = 0.009, = 0.009, respectively). There was no significant difference in the Barthel Index scores of surviving patients. Among the five patients who underwent MoCA and DTI, four had a score of 0/5 for delayed recall (no cue), while the remaining patient had a score of 2/5. All five patients were able to achieve a score of 5/5 with classification and multiple-choice prompts, and had sparse or broken corpus callosum (or other) fibre bundles. TAGMIC treatment can reduce mortality due to severe Japanese encephalitis. The memory loss of surviving patients is mainly due to a disorder of the memory retrieval process, which may be related to the breakage of related fibre bundles.
目前,日本脑炎尚无有效的治疗方法,其发病率和死亡率都很高。本研究评估了更昔洛韦、甲泼尼龙和免疫球蛋白联合疗法(TAGMIC)在降低日本脑炎患者认知障碍和死亡率方面的有效性。我们回顾性评估了31名被诊断为日本脑炎并入住重症监护病房患者的临床数据。根据治疗方案,将患者分为TAGMIC组和非TAGMIC组。我们比较了两组之间60天、6个月的死亡率及总死亡率和生存曲线。我们还比较了巴氏指数评分、蒙特利尔认知评估(MoCA)评分和弥散张量成像(DTI)结果。两组之间30天死亡率或Kaplan-Meier生存曲线无显著差异。与非TAGMIC组相比,TAGMIC组的60天、6个月及总死亡率均显著降低(分别为P = 0.043、P = 0.018和P = 0.018)(分别为0、0、0对31.25%、37.5%、37.5%)。两组之间60天、6个月及总Kaplan-Meier生存曲线有显著差异(分别为P = 0.020、P = 0.009、P = 0.009)。存活患者的巴氏指数评分无显著差异。在接受MoCA和DTI检查的5名患者中,4名在延迟回忆(无提示)时得分为0/5,而其余1名患者得分为2/5。所有5名患者在分类和多项选择提示下均能达到5/5的评分,且胼胝体(或其他)纤维束稀疏或中断。TAGMIC治疗可降低重症日本脑炎的死亡率。存活患者的记忆丧失主要是由于记忆检索过程紊乱,这可能与相关纤维束的中断有关。